ArticleOPEN ACCESS

Tumour-agnostic drugs in paediatric cancers

British Journal of Cancer
DOI: 10.1038/s41416-020-0770-5
6Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.

Cite

CITATION STYLE

APA

Chisholm, J. C., Carceller, F., & Marshall, L. V. (2020, May 12). Tumour-agnostic drugs in paediatric cancers. British Journal of Cancer. Springer Nature. https://doi.org/10.1038/s41416-020-0770-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free